المؤلفون: Muthiah, Chandrasekar, Lian, Qinghua, Benz, Samantha, Szabo, Aniko, Hoffmeister, Karin, Botero, Juliana Perez, Michaelis, Laura C

المصدر: All Other Contributions

مصطلحات موضوعية: immunethrombocytopenia, ITP, neuraminidase inhibitor, Hematology, Pharmacy and Pharmacology

العلاقة: https://institutionalrepository.aah.org/allother/776Test; https://libkey.io/libraries/1712/10.3324/haematol.2023.283731Test

الإتاحة: https://doi.org/10.3324/haematol.2023.283731Test
https://institutionalrepository.aah.org/allother/776Test

المؤلفون: Shah, Nirav N., Atallah, Ehab L., Abedin, Sameem, Murthy, Guru Subramanian Guru, Runaas, Lyndsey, Michaelis, Laura C., Longo, Walter, Furqan, Fateeha, Bucklan, Daniel, Szabo, Aniko, Kearl, Tyce, Schneider, Dina, Palen, Katie, Johnson, Bryon D, Hematti, Peiman, Fenske, Timothy S., Hamadani, Mehdi

المصدر: Transplantation and Cellular Therapy ; volume 30, issue 2, page S35-S36 ; ISSN 2666-6367

مصطلحات موضوعية: Transplantation, Cell Biology, Hematology, Molecular Medicine, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.jtct.2023.12.052Test
https://api.elsevier.com/content/article/PII:S2666636723017876?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666636723017876?httpAccept=text/plainTest

المؤلفون: Carlson, Karen-Sue, Cunningham, Ashley, Stahl, Maximilian, Winer, Eric, Michaelis, Laura C.

المصدر: Acta Haematologica; 2024, Vol. 147 Issue 2, p122-133, 11p

مصطلحات موضوعية: ACUTE myeloid leukemia, NOSOLOGY, CONSORTIA, CLASSIFICATION, MYELODYSPLASTIC syndromes

الشركة/الكيان: WORLD Health Organization

مستخلص: Background: The classification of acute myeloid leukemia (AML) has long been overseen by the World Health Organization (WHO) and published into a series of "Blue Books." These ledgers serve as the reference manual for AML classification and, in turn, classification-based treatment decisions. In 2022, two separate groups, each of which included hematologic oncologists, hematopathologists, and geneticists – developed and published two parallel classification systems for AML. One is from the WHO (WHO 5th edition), and a second is from an International Advisory Consortium (International Consortium Classification [ICC]). Summary: Both modern classification systems originated from the revised 4th edition of the WHO Blue Books and thus share many similarities. There are never-the-less several important differences with the potential to substantially alter disease classification, access to clinical trials, and treatment decision-making. In this manuscript, we review the organization of the WHO and ICC classification systems for AML with emphasis on their similarities and differences, followed by areas in which their application to clinical scenarios may present difficulties. Key Messages: (1) The ICC and WHO 5th edition are concordant for the majority of AMLs. (2) Key differences between AML classification by the ICC and WHO 5th edition include (a) the overall framework of classification, (b) AML-defining blast threshold, definition of myelodysplasia-related AML, and (c) strategy for assigning therapy-related or germline-associated AML modifiers. [ABSTRACT FROM AUTHOR]

: Copyright of Acta Haematologica is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Solomon, Scott R., Powell, Bayard L., Koprivnikar, Jamie, Lai, Catherine, Male, Heather, Michaelis, Laura C., Newell, Laura F., Sanford, David, Jenkins, Jack, Zelaya, Amy, Coppola, Sheryl, Faderl, Stefan, Walter, Roland B.

المصدر: Cancers; Mar2024, Vol. 16 Issue 5, p915, 11p

مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, PHARMACEUTICAL arithmetic, HEMATOLOGIC malignancies, PATIENT safety, CREATININE, CLINICAL trials, ANTINEOPLASTIC agents, BLOOD collection, DESCRIPTIVE statistics, CYTARABINE, KIDNEY diseases, COMPARATIVE studies, URINE collection & preservation, DAUNOMYCIN

مصطلحات جغرافية: UNITED States

مستخلص: Simple Summary: CPX-351 has been approved for the treatment of acute myeloid leukemia. Previous studies have indicated that dose adjustment is not warranted for patients with mild to moderate renal impairment. However, the effect of severe renal impairment on the use of CPX-351 has not been established. In this study, we evaluated CPX-351 in patients with normal renal function and in patients with moderate and severe renal impairment. We compared how CPX-351 moves through the body, as well as the safety of the drug, in these different patient groups. The results suggest that CPX-351 dose adjustment is not required for patients with hematologic malignancies with moderate or severe renal impairment. This open-label phase 1 study (clinicaltrials.gov, NCT03555955) assessed CPX-351 pharmacokinetics (PK) and safety in patients with hematologic malignancies with normal or impaired renal function. Patients were enrolled into three cohorts based on their creatinine clearance (CrCl): ≥90 mL/min (Cohort 1, normal renal function, n = 7), 30 to <59 mL/min (Cohort 2, moderate renal impairment, n = 8), or <30 mL/min (Cohort 3, severe renal impairment, n = 6). Patients received intravenous CPX-351 for initial induction; blood and urine samples were collected for PK analysis. The primary objective was to assess the PK parameters for cytarabine, daunorubicin, and their respective metabolites, arabinosyluracil (Ara-U) and daunorubicinol. Renal impairment did not significantly impact the cytarabine, daunorubicin, or daunorubicinol exposure, but it caused a slight increase in the Ara-U exposure. The CPX-351 side effect profile was similar in patients with impaired renal function compared to those with normal renal function. All the patients reported ≥1 treatment-emergent adverse event (TEAE), most commonly febrile neutropenia and nausea (57% each) and hyperglycemia (43%); no patients discontinued treatment due to TEAEs. These data suggest that CPX-351 dose adjustment is not required for patients with hematologic malignancies with moderate or severe renal impairment. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Corrao, Kristen, Rezwan, Siam, Atallah, Ehab, Michaelis, Laura C, Runaas, Lyndsey, Harrington, Alexandra M., Abedin, Sameem

المصدر: Leukemia Research Reports ; volume 17, page 100329 ; ISSN 2213-0489

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.lrr.2022.100329Test
https://api.elsevier.com/content/article/PII:S2213048922000413?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2213048922000413?httpAccept=text/plainTest

المؤلفون: Berce, Philip C., Cardwell, Leah, Essenmacher, Amber N., Michaelis, Laura C., Wanat, Karolyn A.

المصدر: JAAD Case Reports ; volume 22, page 110-113 ; ISSN 2352-5126

مصطلحات موضوعية: Dermatology

الإتاحة: https://doi.org/10.1016/j.jdcr.2022.01.017Test
https://api.elsevier.com/content/article/PII:S2352512622000571?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2352512622000571?httpAccept=text/plainTest

المؤلفون: Chang, Yaping, Guyatt, Gordon H., Teich, Trevor, Dawdy, Jamie L., Shahid, Shaneela, Altman, Jessica K., Stone, Richard M., Sekeres, Mikkael A., Mukherjee, Sudipto, LeBlanc, Thomas W., Abel, Gregory A., Hourigan, Christopher S., Litzow, Mark R., Michaelis, Laura C., Alibhai, Shabbir M. H., Desai, Pinkal, Buckstein, Rena, MacEachern, Janet, Brignardello-Petersen, Romina

المساهمون: Bertolini, Francesco

المصدر: PLOS ONE ; volume 16, issue 3, page e0249087 ; ISSN 1932-6203

الوصف: To compare the effectiveness and safety of intensive antileukemic therapy to less-intensive therapy in older adults with acute myeloid leukemia (AML) and intermediate or adverse cytogenetics, we searched the literature in Medline, Embase, and CENTRAL to identify relevant studies through July 2020. We reported the pooled hazard ratios (HRs), risk ratios (RRs), mean difference (MD) and their 95% confidence intervals (CIs) using random-effects meta-analyses and the certainty of evidence using the GRADE approach. Two randomized trials enrolling 529 patients and 23 observational studies enrolling 7296 patients proved eligible. The most common intensive interventions included cytarabine-based intensive chemotherapy, combination of cytarabine and anthracycline, or daunorubicin/idarubicin, and cytarabine plus idarubicin. The most common less-intensive therapies included low-dose cytarabine alone, or combined with clofarabine, azacitidine, and hypomethylating agent-based chemotherapy. Low certainty evidence suggests that patients who receive intensive versus less-intensive therapy may experience longer survival (HR 0.87; 95% CI, 0.76–0.99), a higher probability of receiving allogeneic hematopoietic stem cell transplantation (RR 6.14; 95% CI, 4.03–9.35), fewer episodes of pneumonia (RR, 0.25; 95% CI, 0.06–0.98), but a greater number of severe, treatment-emergent adverse events (RR, 1.34; 95% CI, 1.03–1.75), and a longer duration of intensive care unit hospitalization (MD, 6.84 days longer; 95% CI, 3.44 days longer to 10.24 days longer, very low certainty evidence). Low certainty evidence due to confounding in observational studies suggest superior overall survival without substantial treatment-emergent adverse effect of intensive antileukemic therapy over less-intensive therapy in older adults with AML who are candidates for intensive antileukemic therapy.

الإتاحة: https://doi.org/10.1371/journal.pone.0249087Test

المؤلفون: Mushtaq, Muhammad Umair, Harrington, Alexandra M., Chaudhary, Sibgha Gull, Michaelis, Laura C., Carlson, Karen-Sue B., Abedin, Sameem, Runass, Lyndsey, Callander, Natalie S., Juckett, Mark B., Hall, Aric C., Hematti, Peiman, Mattison, Ryan J., Atallah, Ehab L., Guru Murthy, Guru Subramanian

المصدر: Transplantation and Cellular Therapy ; volume 27, issue 3, page S130-S131 ; ISSN 2666-6367

مصطلحات موضوعية: Transplantation, Cell Biology, Hematology, Molecular Medicine, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/s2666-6367Test(21)00165-2
https://api.elsevier.com/content/article/PII:S2666636721001652?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666636721001652?httpAccept=text/plainTest

المؤلفون: Mishra, Asmita, Preussler, Jaime M., Al-Mansour, Zeina, Bachanova, Veronika, Bhatt, Vijaya Raj, Bredeson, Christopher, Chhabra, Saurabh, D’Souza, Anita, Dahi, Parastoo B., DeFilipp, Zack, Gowda, Lohith, Danaher Hacker, Eileen, Hashmi, Shahrukh K., Howard, Dianna S., Jakubowski, Ann A., Jayani, Reena, Johnston, Laura, Koll, Thuy, Lin, Richard J., McCurdy, Shannon R., Michaelis, Laura C., Muffly, Lori, Nathwani, Nitya, Olin, Rebecca L., Popat, Uday R., Rodriguez, Cesar, Rosko, Ashley, Runaas, Lyndsey, Sabloff, Mitchell, Shore, Tsiporah B., Shune, Leyla, Sorror, Mohamed L., Sung, Anthony D., Ustun, Celalettin, Wood, William, Burns, Linda J., Artz, Andrew S.

المساهمون: School of Nursing

المصدر: Publisher

مصطلحات موضوعية: Hematopoietic Cell Transplantation, geriatric assessment, older patients

الوصف: Background Despite improvements in conditioning regimens and supportive care having expanded the curative potential of HCT, underutilization of HCT in older adults persists (Bhatt VR et al, BMT 2017). Therefore, we conducted a survey of transplant physicians (TP) to determine their perceptions of the impact of older age (≥60 years) on HCT candidacy and utilization of tools to gauge candidacy. Methods We conducted a 23-item, online cross-sectional survey of adult physicians recruited from the Center for International Blood and Marrow Transplant Research between May and July 2019. Results 175/770 (22.7%) TP completed the survey; majority of respondents were 41-60 years old, male, and practicing in a teaching hospital. Over 75% were at centers performing ≥50 HCT per year. When considering regimen intensity, most (96%, n=168) had an upper age limit (UAL) for using a myeloablative regimen (MAC), with only 29 physicians (17%) stating they would consider MAC for patients ≥70 years. In contrast, when considering a reduced intensity/non-myeloablative conditioning (RIC/NMA), 8%, (n=13), 54% (n=93), and 20% (n=35) stated that age 70, 75, and 80 years respectively would be the UAL to use this approach, with 18% (n=31) reporting no UAL. TP agreed that Karnofsky Performance Score (KPS) could exclude older pts for HCT, with 39.1% (n=66), 42.6% (n=72), and 11.4% (n=20) requiring KPS of ≥70, 80, and 90, respectively. The majority (n=92, 52.5%) indicated an HCT-comorbidity index threshold for exclusion, mostly ranging from ≥3 to ≥ 5. Almost all (89.7%) endorsed the need for a better health assessment of pre-HCT vulnerabilities to guide candidacy for pts ≥60 with varied assessments being utilized beyond KPS (Figure 1). However, the majority of centers rarely (33.1%) or never (45.7%) utilize a dedicated geriatrician/geriatric-oncologist to assess alloHCT candidates ≥60 yrs. The largest barriers to performing GA included uncertainty about which tools to use, lack of knowledge and training, and lack of appropriate clinical support ...

وصف الملف: application/pdf

العلاقة: Biology of Blood and Marrow Transplantation; Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V. R., Bredeson, C., Chhabra, S., D’Souza, A., Dahi, P. B., DeFilipp, Z., Gowda, L., Hacker, E. D., Hashmi, S. K., Howard, D. S., Jakubowski, A. A., Jayani, R., Johnston, L., Koll, T., Lin, R. J., … Artz, A. S. (2020). Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. Biology of Blood and Marrow Transplantation, 26(3, Supplement), S45–S46. https://doi.org/10.1016/j.bbmt.2019.12.115Test; https://hdl.handle.net/1805/28222Test

الإتاحة: https://doi.org/10.1016/j.bbmt.2019.12.115Test
https://hdl.handle.net/1805/28222Test

المؤلفون: Othus, Megan, Thomas, Ian, Wang, Xu, Ariti, Cono, Mehta, Priyanka, Sydenham, Mia, Hills, Robert K., Burnett, Alan K., Nand, Sucha, Assouline, Sarit, Michaelis, Laura C., Erba, Harry P., Russell, Nigel, Kerr, Kathleen F., Walter, Roland B., Dennis, Mike

العلاقة: Othus, M. et al. (2023) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia and Lymphoma , 64(1), pp. 250-252. (doi:10.1080/10428194.2022.2131416 ) (PMID:36226777)

الإتاحة: https://doi.org/10.1080/10428194.2022.2131416Test
https://eprints.gla.ac.uk/282773Test/